Katherine Stadler, APRN
Adult Health · Topeka, KSNPI 1629578943
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$609
- Novo Nordisk$594
- Insulet Corporation$528
- Mannkind Corporation$409
- Dexcom, Inc.$403
- Tandem Diabetes Care, Inc.$227
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,883100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $609 |
| Novo Nordisk | 49 | $594 |
| Insulet Corporation | 48 | $528 |
| Mannkind Corporation | 21 | $409 |
| Dexcom, Inc. | 14 | $403 |
| Tandem Diabetes Care, Inc. | 9 | $227 |
| Cequr Corporation | 2 | $224 |
| Corcept Therapeutics | 10 | $200 |
| AstraZeneca | 11 | $190 |
| Amgen | 13 | $187 |
| Radius Health, Inc. | 5 | $147 |
| Sanofi-aventis U.S. LLC | 8 | $143 |
| AbbVie | 9 | $140 |
| Xeris Pharmaceuticals, Inc. | 8 | $135 |
| Boehringer Ingelheim | 8 | $124 |
| Medtronic | 5 | $123 |
| Averitas Pharma Inc. | 4 | $97 |
| IBSA Pharma Inc. | 4 | $77 |
| Bayer | 4 | $61 |
| Ascendis Pharma Endocrinology Inc | 2 | $59 |
| Antares Pharma, Inc. | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $22 |
| BETA Bionics, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Abbott | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$126
How this compares
$4,897 in reported general payments places this provider in the 90th percentile of 155 adult health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 369 | $463,629 |
| MounjaroTirzepatide | 185 | $235,373 |
| JardianceEmpagliflozin | 262 | $229,472 |
| FarxigaDapagliflozin Propanediol | 206 | $159,878 |
| JanuviaSitagliptin Phosphate | 102 | $91,396 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 114 | $89,333 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $87,477 |
| Tresiba Flextouch U-100Insulin Degludec | 148 | $85,677 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 37 | $76,540 |
| TrulicityDulaglutide | 68 | $72,859 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 94 | $46,720 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $41,432 |
| Novolog FlexpenInsulin Aspart | 163 | $38,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 286 | $34,074 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $34,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $594 | $505,328459 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $609 | $317,595316 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $124 | $277,017320 claims |
| AstraZenecaFarxiga | $190 | $159,878206 claims |
| Sanofi-aventis U.S. LLCLantus | $143 | $3,60332 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,334323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 155 adult health providers in Kansas.
Other adult health in Topeka
- Laura SidlingerTopeka$4K
- Kurtis CarricoTopeka$2K
- Megan FeighnyTopeka$1K
- Valerie DavisWichita$100K
- Julianna BergkampWichita$18K
- Lauren FieldsOverland Park$12K
- Tina LegaultOverland Park$12K
- Candace KoirthPratt$11K
- Jennifer SurpriseKansas City$8K
- Angela leWichita$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.